Effects of pitavastatin in japanese patients with chronic heart failure - The pitavastatin heart failure study (PEARL study) -

Hiroyuki Takano, Hiroshi Mizuma, Yoichi Kuwabara, Yasunori Sato, Satoshi Shindo, Norihiko Kotooka, Daisuke Fujimatsu, Yoshio Kobayashi, Teruo Inoue, Koichi Node, Issei Komuro

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Recent clinical trials using rosuvastatin, a hydrophilic statin, did not show beneficial effects on cardiovascular events in patients with heart failure. We examined the cardioprotective effects of pitavastatin, a lipophilic statin, on Japanese patients with chronic heart failure (CHF). Methods and Results: A total of 574 Japanese patients with CHF were randomly assigned to the pitavastatin group (n=288) or the control group (n=286). There was no significant difference between the 2 groups for the primary outcome, which was a composite of cardiac death and hospitalization for worsening HF (adjusted hazard ratio (aHR): 0.922, 95% confidence interval (CI): 0.632-1.345, P=0.672). A strongly significant statistical interaction between the effect of pitavastatin and left ventricular ejection fraction (LVEF) was found (P=0.004). In patients with LVEF ≥30%, a significant reduction in the primary outcome (aHR: 0.525, 95% CI: 0.308-0.896, P=0.018) was observed in the pitavastatin group. Pitavastatin did not show any effects on the primary outcome (aHR: 1.582, 95% CI: 0.890-2.813, P=0.118) in the subgroup of patients with LVEF <30%. Conclusions: Pitavastatin did not reduce cardiac death or hospitalization for worsening HF in Japanese patients with CHF. (UMIN-ID: UMINC000000428).

Original languageEnglish
Pages (from-to)917-925
Number of pages9
JournalCirculation Journal
Volume77
Issue number4
DOIs
Publication statusPublished - 2013 Apr 3
Externally publishedYes

Fingerprint

Heart Failure
Stroke Volume
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Confidence Intervals
Hospitalization
pitavastatin
Clinical Trials
Control Groups

Keywords

  • Heart failure
  • Hypercholesterolemia
  • Pitavastatin
  • Randomized controlled trial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of pitavastatin in japanese patients with chronic heart failure - The pitavastatin heart failure study (PEARL study) -. / Takano, Hiroyuki; Mizuma, Hiroshi; Kuwabara, Yoichi; Sato, Yasunori; Shindo, Satoshi; Kotooka, Norihiko; Fujimatsu, Daisuke; Kobayashi, Yoshio; Inoue, Teruo; Node, Koichi; Komuro, Issei.

In: Circulation Journal, Vol. 77, No. 4, 03.04.2013, p. 917-925.

Research output: Contribution to journalArticle

Takano, H, Mizuma, H, Kuwabara, Y, Sato, Y, Shindo, S, Kotooka, N, Fujimatsu, D, Kobayashi, Y, Inoue, T, Node, K & Komuro, I 2013, 'Effects of pitavastatin in japanese patients with chronic heart failure - The pitavastatin heart failure study (PEARL study) -', Circulation Journal, vol. 77, no. 4, pp. 917-925. https://doi.org/10.1253/circj.CJ-12-1062
Takano, Hiroyuki ; Mizuma, Hiroshi ; Kuwabara, Yoichi ; Sato, Yasunori ; Shindo, Satoshi ; Kotooka, Norihiko ; Fujimatsu, Daisuke ; Kobayashi, Yoshio ; Inoue, Teruo ; Node, Koichi ; Komuro, Issei. / Effects of pitavastatin in japanese patients with chronic heart failure - The pitavastatin heart failure study (PEARL study) -. In: Circulation Journal. 2013 ; Vol. 77, No. 4. pp. 917-925.
@article{6c41483acef14d0795240b54ef8b3481,
title = "Effects of pitavastatin in japanese patients with chronic heart failure - The pitavastatin heart failure study (PEARL study) -",
abstract = "Background: Recent clinical trials using rosuvastatin, a hydrophilic statin, did not show beneficial effects on cardiovascular events in patients with heart failure. We examined the cardioprotective effects of pitavastatin, a lipophilic statin, on Japanese patients with chronic heart failure (CHF). Methods and Results: A total of 574 Japanese patients with CHF were randomly assigned to the pitavastatin group (n=288) or the control group (n=286). There was no significant difference between the 2 groups for the primary outcome, which was a composite of cardiac death and hospitalization for worsening HF (adjusted hazard ratio (aHR): 0.922, 95{\%} confidence interval (CI): 0.632-1.345, P=0.672). A strongly significant statistical interaction between the effect of pitavastatin and left ventricular ejection fraction (LVEF) was found (P=0.004). In patients with LVEF ≥30{\%}, a significant reduction in the primary outcome (aHR: 0.525, 95{\%} CI: 0.308-0.896, P=0.018) was observed in the pitavastatin group. Pitavastatin did not show any effects on the primary outcome (aHR: 1.582, 95{\%} CI: 0.890-2.813, P=0.118) in the subgroup of patients with LVEF <30{\%}. Conclusions: Pitavastatin did not reduce cardiac death or hospitalization for worsening HF in Japanese patients with CHF. (UMIN-ID: UMINC000000428).",
keywords = "Heart failure, Hypercholesterolemia, Pitavastatin, Randomized controlled trial",
author = "Hiroyuki Takano and Hiroshi Mizuma and Yoichi Kuwabara and Yasunori Sato and Satoshi Shindo and Norihiko Kotooka and Daisuke Fujimatsu and Yoshio Kobayashi and Teruo Inoue and Koichi Node and Issei Komuro",
year = "2013",
month = "4",
day = "3",
doi = "10.1253/circj.CJ-12-1062",
language = "English",
volume = "77",
pages = "917--925",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "4",

}

TY - JOUR

T1 - Effects of pitavastatin in japanese patients with chronic heart failure - The pitavastatin heart failure study (PEARL study) -

AU - Takano, Hiroyuki

AU - Mizuma, Hiroshi

AU - Kuwabara, Yoichi

AU - Sato, Yasunori

AU - Shindo, Satoshi

AU - Kotooka, Norihiko

AU - Fujimatsu, Daisuke

AU - Kobayashi, Yoshio

AU - Inoue, Teruo

AU - Node, Koichi

AU - Komuro, Issei

PY - 2013/4/3

Y1 - 2013/4/3

N2 - Background: Recent clinical trials using rosuvastatin, a hydrophilic statin, did not show beneficial effects on cardiovascular events in patients with heart failure. We examined the cardioprotective effects of pitavastatin, a lipophilic statin, on Japanese patients with chronic heart failure (CHF). Methods and Results: A total of 574 Japanese patients with CHF were randomly assigned to the pitavastatin group (n=288) or the control group (n=286). There was no significant difference between the 2 groups for the primary outcome, which was a composite of cardiac death and hospitalization for worsening HF (adjusted hazard ratio (aHR): 0.922, 95% confidence interval (CI): 0.632-1.345, P=0.672). A strongly significant statistical interaction between the effect of pitavastatin and left ventricular ejection fraction (LVEF) was found (P=0.004). In patients with LVEF ≥30%, a significant reduction in the primary outcome (aHR: 0.525, 95% CI: 0.308-0.896, P=0.018) was observed in the pitavastatin group. Pitavastatin did not show any effects on the primary outcome (aHR: 1.582, 95% CI: 0.890-2.813, P=0.118) in the subgroup of patients with LVEF <30%. Conclusions: Pitavastatin did not reduce cardiac death or hospitalization for worsening HF in Japanese patients with CHF. (UMIN-ID: UMINC000000428).

AB - Background: Recent clinical trials using rosuvastatin, a hydrophilic statin, did not show beneficial effects on cardiovascular events in patients with heart failure. We examined the cardioprotective effects of pitavastatin, a lipophilic statin, on Japanese patients with chronic heart failure (CHF). Methods and Results: A total of 574 Japanese patients with CHF were randomly assigned to the pitavastatin group (n=288) or the control group (n=286). There was no significant difference between the 2 groups for the primary outcome, which was a composite of cardiac death and hospitalization for worsening HF (adjusted hazard ratio (aHR): 0.922, 95% confidence interval (CI): 0.632-1.345, P=0.672). A strongly significant statistical interaction between the effect of pitavastatin and left ventricular ejection fraction (LVEF) was found (P=0.004). In patients with LVEF ≥30%, a significant reduction in the primary outcome (aHR: 0.525, 95% CI: 0.308-0.896, P=0.018) was observed in the pitavastatin group. Pitavastatin did not show any effects on the primary outcome (aHR: 1.582, 95% CI: 0.890-2.813, P=0.118) in the subgroup of patients with LVEF <30%. Conclusions: Pitavastatin did not reduce cardiac death or hospitalization for worsening HF in Japanese patients with CHF. (UMIN-ID: UMINC000000428).

KW - Heart failure

KW - Hypercholesterolemia

KW - Pitavastatin

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=84875549601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875549601&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-12-1062

DO - 10.1253/circj.CJ-12-1062

M3 - Article

C2 - 23502990

AN - SCOPUS:84875549601

VL - 77

SP - 917

EP - 925

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 4

ER -